IP Library Granted Patent US 7,449,481
Granted Patent B2
US 7,449,481 · App. 11/104,091 · Granted Nov 11, 2008

Thio-substituted biaryl-methanesulfinyl derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,449,481
App. No.
11/104,091
Granted
Nov 11, 2008
Kind
B2
Abstract

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R 1 , R 2 , R 4 , R 5 , q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.

Claims (2395)

1. A compound of Formula (I):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof,

wherein:

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or

5 to 14 membered heteroaryl group substituted by 0-5 R 3 , wherein said heteroaryl group is selected from phenoxathiinyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, imidazopyridinyl, triazolyl, purine and 2-benzo [1,4]dioxine;

Y is C 1 -C 6 alkylene substituted with 0-3 R 20A ;

R 1 is selected from H, C(═O)NR 12 R 13 , C(═N)NR 12 R 13 , OC(═O)NR 12 R 13 , NR 21 C(═O)NR 12 R 13 , NR 21 S(═O) 2 NR 12 R 13 , —(C 6 -C 10 aryl)-NR 12 R 13 wherein said aryl is substituted with 0-3 R 20 ; NR 21 C(═O)R 14 , C(═O)R 14 , C(═O)OR 11 , OC(═O)R 11 , and NR 21 S(═O) 2 R 11 ;

R 2 is selected from H, F, Cl, Br, I, OR 16 , OR 25 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NR 15 C(═O)R 16 , NR 15 CO 2 R 16 , OC(═O)NR 17 R 18 , NR 15 C(═S)R 16 , SR 16 , S(═O)R 16 , and S(═O) 2 R 16 ;

alternatively, two R 2 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 3 is selected from H, F, Cl, Br, I, OR 16 , OCF 3 , OR 25 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , CH 2 OR 16 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl, C 7 -C 10 arylalkyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NR 15 C(═O)R 16 , NR 15 CO 2 R 16 , OC(═O)NR 17 R 18 , NR 15 C(═S)R 16 , SR 16 , S(═O)R 16 , S(═O) 2 R 16 , and NR 15 S(═O ) 2 R 16 ;

alternatively, two R 3 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 4 and R 5 at each occurrence are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

alternatively, R 4 and R 5 , together with the carbon atom to which they are attached, form a 3-7 membered spirocyclic ring;

R 11 at each occurrence is independently selected from H, C 1 -C 6 alkyl substituted with 0-3 R 20 ; and C 6 -C 10 aryl substituted with 0-3 R 20 ;

R 12 and R 13 at each occurrence are each independently selected from H, C 1 -C 6 alkyl substituted with 0-3 R 20 and C 6 -C 10 aryl substituted with 0-3 R 20 ;

alternatively, R 12 and R 13 , together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring substituted with 0-3 R 20 , wherein said heterocyclic ring is selected from piperazinyl, piperidinyl and pyrrolidinyl;

R 14 at each occurrence is independently selected from C 1 -C 6 alkyl substituted with 0-3 R 20 ; C 6 -C 10 aryl substituted with 0-3 R 20 ; C 6 -C 10 and C 7 -C 10 arylalkyl substituted with 0-3 R 20 ;

R 15 at each occurrence is independently selected from H and C 1 -C 6 alkyl;

R 16 at each occurrence is independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl;

R 17 and R 18 at each occurrence are each independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl;

R 20 at each occurrence is independently selected from F, Cl, Br, I, OH, OR 22 , OR 25 , NR 23 R 24 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl substituted by 0-1 R 26 ; C 7 -C 10 arylalkyl, ═O, C(═O)R 22 , C(═O)OR 22 , OC(═O)R 22 , C(═O)NR 23 R 24 , NR 21 C(═O)R 22 ,NR 21 CO 2 R 22 , OC(═O)NR 23 R 24 , NR 21 C(═S)R 22 , SR 22 , S(═O)R 22 , and S(═O) 2 R 22 ;

R 20A at each occurrence is independently selected from F, Cl, OH, C 1 -C 4 alkoxy, CF 3 , C 1 -C 4 alkyl, C 1 -C 4 alkyl-OH, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, and C 3 -C 5 cycloalkyl;

R 21 at each occurrence is independently selected from H and C 1 -C 6 alkyl;

R 22 at each occurrence is independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, and C 6 -C 10 aryl;

R 23 and R 24 at each occurrence are each independently selected from H, C 1 -C 6 alkyl, and C 6 -C 10 aryl;

R 25 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;

R 26 at each occurrence is independently selected from H, F, Cl, Br, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy;

x is 0, 1, 2, 3, or 4; and

q is 1 or 2;

provided,

when Y is —CH 2 —, Ar is phenyl substituted by 0-5 R 3 , and —C(R 4 )(R 5 )— is —CH(C 1 -C 3 alkyl)—, then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Y is —CH 2 —, R 1 is H, C(═O)OR 11 , or C(═O)NR 12 R 13 ; Ar is phenyl substituted by 0-2 R 3 , and R 3 is H, F, Cl, Br, I, CH 3 , OCH 3 , SCH 3 , CN, NO 2 , or methylenedioxyphenyl; then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Ar is imidazopyridine substituted by 0-5 R 3 , Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when Ar is in the meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring and Ar is a heteroaryl group attached to the phenyl ring through a nitrogen atom, then Ar is pyrrolyl, indolyl, triazolyl, or 1,3-dihydroisoindolyl;

when Y is —CH 2 — and Ar is pyridyl substituted by a nitro, a methyl, a second methyl, and a C(═O)OC 3 H 7 group, then R 1 is not H;

when Y is —CH 2 — and Ar is a purine or imidazopyridine, substituted by 0-5 R 3 , then R 1 is not H;

when q is 1, Y is butylene and Ar is phenyl, substituted by 0-5 R 3 , in the para position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H;

when q is 1, Y is —CH 2 — or —CH 2 —CH 2 —, and Ar is pyrrolyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring; then R 1 is not H;

when q is 1, R 2 is OH, and Ar is phenyl of cycloalkenyl; then R 1 is not H or C(═O)OR 11 ;

when q is 1, Y is —CH 2 —, R 4 is H, R 5 is H, and Ar is phenyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H;

when q is 2, then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

when q is 2, Y is —CH 2 —, R 4 is H, R 5 is H, and Ar is 1, 2-(methylenedioxy)-phenyl, then Ar is in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring; and

when q is 2, and Ar is phenyl in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring, then R 1 is not H.

2. A compound of claim 1 , wherein q is 1.

3. A compound of claim 1 , wherein R 1 is C(═O)NR 12 R 13 .

4. A compound of claim 1 , wherein Y is —CH 2 —.

5. A compound of claim 1 , wherein Ar is phenyl substituted by 0-5 R 3 .

6. A compound of claim 1 , wherein Ar is in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring.

7. A compound of claim 1 of Formula (Ib):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof.

8. A compound of claim 1 of Formula (Ie):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof,

wherein:

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or

5 to 14 membered heteroaryl group substituted by 0-5 R 3 wherein said heteroaryl group is selected from phenoxathiinyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, and 2-benzo [1,4]dioxine;

R 2 is selected from H, F, Cl, Br, I, OR 16 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NHC(═O)R 16 , NHCO 2 R 16 , OC(═O)NR 17 R 18 , NHC(═S)R 16 , and S(═O) 2 R 16 ;

alternatively, two R 2 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 3 is selected from H, F, Cl, Br, I, OR 16 , OCF 3 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , CH 2 OR 16 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl, C 7 -C 10 arylalkyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NHC(═O)R 16 , NHCO 2 R 16 , OC(═O)NR 17 R 18 , NHC(═S)R 16 , SR 16 , S(═O)R 16 , S(═O) 2 R 16 , and NHS(═O) 2 R 16 ;

alternatively, two R 3 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 20 at each occurrence is independently selected from F, Cl, Br, I, OH, OR 22 , NR 23 R 24 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl substituted by 0-1 R 26 ; C 7 -C 10 arylalkyl, ═O, C(═O)R 22 , C(═O)OR 22 , OC(═O)R 22 , C(═O)NR 23 R 24 , NHC(═O)R 22 , NHCO 2 R 22 , OC(═O)NR 23 R 24 , NHC(═S)R 22 , SR 22 , S(═O)R 22 , and S(═O) 2 R 22 ;

R 22 at each occurrence is independently selected from H, C 1 -C 4 alkyl, C 1 -C 4 alkyl-OH, and C 6 -C 10 aryl;

R 23 and R 24 at each occurrence are each independently selected from H, C 1 -C 4 alkyl, and C 6 -C 10 aryl; and

R 26 at each occurrence is independently selected from H, F, Cl, Br, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy; and

provided,

when Ar is phenyl substituted by 0-2 R 3 , and R 3 is H, F, Cl, Br, I, CH 3 , OCH 3 , SCH 3 , CN, NO 2 , or methylenedioxyphenyl; then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring.

9. A compound of claim 8 , wherein Ar is phenyl substituted by 0-5 R 3 , wherein said Ar group is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring.

10. A compound of claim 8 , wherein Ar is C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; wherein said Ar group is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring.

11. A compound of claim 8 , wherein Ar is a 5 to 14 membered heteroaryl group substituted by 0-5 R 3 , wherein said heteroaryl group comprises one, two, or three heteroatoms selected from N, O, S or Se; wherein said 5 to 14 membered heteroaryl group is selected from phenoxathiinyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, and 2-benzo[1,4]dioxine; wherein said Ar group is in the ortho or meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring.

12. A compound of claim 8 of Formula (If):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof.

13. A compound of claim 8 of Formula (Ig):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof.

14. A compound of claim 8 of Formula (Ih):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof.

15. A compound of claim 8 , wherein Ar is phenyl substituted by 0-5 R 3 , wherein said Ar group is in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring.

16. A compound of claim 1 of Formula (I):

and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof,

wherein:

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or a 5 to 10 membered heteroaryl group substituted by 0-5 R 3 , wherein said heteroaryl group comprises one, two, or three heteroatoms selected from N, O, or S; wherein said 5 to 10 membered heteroaryl group is selected from quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, and 2-benzo[1,4]dioxine;

Y is C 1 -C 3 , alkylene substituted with 0-1 R 20A ;

R 1 is selected from H, C(═O)NR 12 R 13 , and C(═O)OR 11 ;

R 2 is selected from H, F, Cl, Br, C 1 -C 4 alkoxy, CN, CF 3 , C 1 -C 4 alkyl;

alternatively, two R 2 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 3 is selected from H, F, Cl, Br, OR 16 , OCF 3 , NR 17 R 18 , NHOH, NO 2 , CN, CF 3 , CH 2 OR 16 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl, C 7 -C 10 , arylalkyl, C(═O)R 16 , C(═O)OR 16 , OC(═O)R 16 , C(═O)NR 17 R 18 , NHC(═O)R 16 , NHCO 2 R 16 , OC(═O)NR 17 R 18 , NHC(═S)R 16 , SR 16 , S(═O)R 16 , S(═O) 2 R 16 , and NHS(═O) 2 R 16 ;

alternatively, two R 3 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 4 and R 5 at each occurrence are independently selected from H, methyl, and ethyl;

R 20 at each occurrence is independently selected from F, Cl, Br, OH, OR 22 , NR 23 R 24 , NHOH, NO 2 , CN, CF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkyl-OH, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, phenyl substituted by 0-1 R 26 ; C 7 -C 10 arylalkyl, ═O, C(═O)R 22 , C(═O)OR 22 , OC(═O)R 22 , C(═O)NR 23 R 24 , NHC(═O)R 22 , NHCO 2 R 22 , OC(═O)NR 23 R 24 , NHC(═S)R 22 , SR 22 , S(═O)R 22 , and S(═O) 2 R 22 ;

R 20A at each occurrence is independently selected from F, Cl, OH, methoxy, ethoxy, methyl, and ethyl; and

R 26 at each occurrence is independently selected from H, F, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy.

17. A compound of claim 16 , wherein q is 1.

18. A compound of claim 16 , wherein q is 1; and Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —.

19. A compound of claim 16 , wherein q is 1; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; and R 1 is C(═O)NR 12 R 13 .

20. A compound of claim 16 , wherein q is 1; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; and R 1 is C(═O)NH 2 .

21. A compound of claim 16 , wherein:

the Ar group is in the ortho position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or a 5 to 10 membered heteroaryl group substituted by 0-5 R 3 , wherein said aryl, cycloalkenyl, or heteroaryl group is selected from phenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, naphthyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)- benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, or 2-benzo[1,4]dioxine;

R 1 is C(═O)NR 12 R 13 .

22. A compound of claim 21 , wherein q is 1.

23. A compound of claim 21 , wherein q is 1; and Ar is phenyl substituted by 0-5 R 3 .

24. A compound of claim 21 , wherein q is 1; Ar is phenyl substituted by 0-5 R 3 ; and Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —.

25. A compound of claim 21 , wherein q is 1; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; Ar is phenyl substituted by 0-3 R 3 ; and R 3 is selected from F, Cl, and Br.

26. A compound of claim 21 , wherein q is 1; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; Ar is phenyl substituted by 0-3 R 3 ; R 3 is selected from F, Cl, and Br; and R 1 is C(═O)NH 2 .

27. A compound of claim 16 , wherein:

the Ar group is in the meta position to the —C(R 4 )(R 5 )— substituent on the core phenyl ring;

Ar is C 6 -C 10 aryl substituted by 0-5 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-5 R 3 ; or a

5 to 10 membered heteroaryl group substituted by 0-5 R 3 , wherein said aryl, cycloalkenyl, and heteroaryl group is selected from phenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, naphthyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, or 2-benzo[1,4]dioxine;

R 1 is H or C(═O)NR 12 R 13 .

28. A compound of claim 27 , wherein q is 1; and R 1 is C(═O)NR 12 R 13 .

29. A compound of claim 27 , wherein q is 1; Ar is phenyl substituted by 0-5 R 3 ; and R 1 is C(═O)NR 12 R 13 .

30. A compound of claim 27 , wherein q is 1; Ar is phenyl substituted by 0-5 R 3 ; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; and R 1 is C(═O)NR 12 R 13 .

31. A compound of claim 27 , wherein q is 1; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; Ar is phenyl substituted by 0-3 R 3 ; R 3 is selected from F, Cl, and Br; and R 1 is C(═O)NR 12 R 13 .

32. A compound of claim 27 , wherein q is 1; Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —; Ar is phenyl substituted by 0-3 R 3 ; R 3 is selected from F, Cl, and Br; and R 1 is C(═O)NH 2 .

33. A compound of claim 1 of Formula (I):

and stereoisomeric forms, mixtures stereoisomeric forms or pharmaceutically acceptable salt forms thereof,

wherein:

Ar is C 6 -C 10 aryl substituted by 0-3 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-3 R 3 ; or a

5 to 10 membered heteroaryl group substituted by 0-1 R 3 ; wherein said aryl, cycloalkenyl, or heteroaryl group is selected from phenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, naphthyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, and 2-benzo[1,4]dioxine;

Y is —CH 2 —, —CH(OCH 3 )—, or —CH 2 CH 2 —;

R 1 is selected from H, C(═O)NR 12 R 13 , and C(═O)OR 11 ;

R 2 is selected from H, Cl, F, methoxy, ethoxy, methyl, ethyl, and propyl;

alternatively, two R 2 groups may be combined to form a methylenedioxy group;

R 3 is selected from H, F, Cl, Br, CF 3 , cyano, OCF 3 , NO 2 , OH, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, CH 2 ═CH 2 , morpholinyl, OR 16 , NR 17 R 18 , CH 2 OR 16 , C(═O)R 16 , C(═O)OR 16 , C(═O)NR 17 R 18 , SR 16 , S(═O)R 16 , S(═O) 2 R 16 , and NHS(═O) 2 R 16 ;

alternatively, two R 3 groups may be combined to form a methylenedioxy group, an ethylenedioxy group, or a propylenedioxy group;

R 4 is H;

R 5 is H;

R 11 at each occurrence is independently selected from H and C 1 -C 6 alkyl substituted with 0-3 R 20 ;

R 12 and R 13 at each occurrence are each independently selected from H, and C 1 -C 3 alkyl substituted with 0-1 R 20 ; wherein said alkyl is methyl, ethyl, n-propyl or i-propyl;

alternatively, R 12 and R 13 , together with the nitrogen to which they are attached, form a 3-7 membered heterocyclic ring substituted with 0-3 R 20 ; wherein said 3-7 membered heterocyclic ring is selected from piperazinyl, piperidinyl, and pyrrolidinyl;

R 16 at each occurrence is independently selected from H, methyl, ethyl, propyl, butyl, and phenyl;

R 17 and R 18 at each occurrence are each independently selected from H, methyl, and ethyl;

R 20 at each occurrence is independently selected from F, Cl, OH, CN, CF 3 , methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, CH 2 CH 2 OH, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, OR 22 , NR 23 R 24 , C(═O)R 22 , C(═O)OR 22 , C(═O)NR 23 R 24 , and phenyl substituted by 0-1 R 26 ;

R 22 at each occurrence is independently selected from H, methyl, ethyl, propyl, butyl, and CH 2 CH 2 OH;

R 23 and R 24 at each occurrence are each independently selected from H, methyl, ethyl, propyl, butyl, and phenyl;

R 26 at each occurrence is independently selected from H, F, methyl, ethyl, propyl, methoxy, and ethoxy; and

x is 0, 1, or 2;

provided,

when Y is —CH 2 —, R 1 is H, C(═O)OR 11 , or C(═O)NR 12 R 13 ; Ar is phenyl substituted by 0-2R 3 , and R 3 is H, F, Cl, Br, I, CH 3 , OCH 3 , SCH 3 , CN, NO 2 , or methylenedioxyphenyl; then Ar is in the ortho or meta position to the —C(R 4 )(R 5 )-substituent on the core phenyl ring.

34. A compound of claim 33 , wherein q is 1.

35. A compound of claim 33 , wherein:

the Ar group is in the ortho position to the —C(R 4 )(R 5 )-substituent on the core phenyl ring;

Ar is C 6 -C 10 aryl substituted by 0-3 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-3 R 3 ; or a

5 to 10 membered heteroaryl group substituted by 0-1 R 3 ; wherein said aryl, cycloalkenyl, or heteroaryl group is selected from phenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, naphthyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, and 2-benzo[1,4]dioxine;

R 1 is C(═O)NR 12 R 13 .

36. A compound of claim 35 , wherein q is 1.

37. A compound of claim 35 , wherein q is 1; and Ar is phenyl substituted by 0-3 R 3 .

38. A compound of claim 35 , wherein q is 1; Y is —CH 2 —; Ar is phenyl substituted by 0-3 R 3 ; and R 3 is selected from F, Cl, and Br.

39. A compound of claim 33 , wherein:

the Ar group is in the meta position to the —C(R 4 )(R 5 )-substituent on the core phenyl ring;

Ar is C 6 -C 10 aryl substituted by 0-3 R 3 ;

C 5 -C 10 cycloalkenyl substituted by 0-3 R 3 ; or a

5 to 10 membered heteroaryl group substituted by 0-1 R 3 ; wherein said aryl, cycloalkenyl, or heteroaryl group is selected from phenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, naphthyl, quinolinyl, isoxazolyl, thienyl, benzothienyl, (1,1-dioxo)-benzothienyl, indolyl, furyl, benzofuryl, pyridyl, seleninyl, 1,3-dihydro-isoindolyl, pyrrolyl, and 2-benzo[1,4]dioxine;

R 1 is H or C(═O)NR 12 R 13 .

40. A compound of claim 39 , wherein q is 1.

41. A compound of claim 39 , wherein q is 1; and Ar is phenyl substituted by 0-3 R 3 .

42. A compound of claim 39 , wherein q is 1; Y is —CH 2 —; Ar is phenyl substituted by 0-3 R 3 ; and R 3 is selected from F, Cl, and Br.

43. A compound selected-from the following Tables 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 14A, 15, 15A 16, 16A, or 17:

TABLE 1

Ex.

Ar

No.

Ar

Position

q

R

1

3-thienyl

ortho

1

CH 2 CONH 2

2

3-thienyl

ortho

1

CH 2 CO—N-pyrrolidinyl

3

3-thienyl

ortho

1

CH 2 CON(CH 3 ) 2

4

3-thienyl

ortho

1

CH 2 CONHCH(CH 3 ) 2

5

3-thienyl

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

6

3-thienyl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

7

3-thienyl

ortho

1

CH 2 CO-l-(4-hydroxy)-piperidinyl

8

3-thienyl

ortho

0

CH—(OCH3)CONH 2

9

3-thienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxamide)-piperazinyl

10

3-thienyl

ortho

1

CH 2 CO-1-(4-carboxamide)-piperazinyl

11

3-thienyl

ortho

1

CH 2 CO-1-(4-phenylcarboxamide)-piperazinyl

12

3-thienyl

ortho

1

CH 2 CO—N-piperazinyl

13

3-thienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxylate)-piperazinyl

14

3-thienyl

ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

15

3-thienyl

ortho

1

CH 2 COOH

16

3-thienyl

ortho

2

CH 2 CO-1-(4-acetyl)-piperazinyl

17

5-chloro-2-

ortho

1

CH 2 CONH 2

thienyl

18

4-methyl-3-

ortho

1

CH 2 CONH 2

thienyl

19

3-thienyl

meta

1

CH 2 CONH 2

20

3-thienyl

meta

1

CH 2 CO—N-pyrrolidinyl

21

3-thienyl

meta

1

CH 2 CON(CH 3 ) 2

22

3-thienyl

meta

1

CH 2 CONHCH(CH 3 ) 2

23

3-thienyl

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

24

3-thienyl

meta

1

CH 2 CON(CH 2 ) 2 OH

25

3-thienyl

meta

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

26

3-thienyl

meta

1

CH 2 CO-1-(4-phenyl)-piperazinyl

27

3-thienyl

meta

1

CH 2 CO-1-(4-ethylcarbaxylate)-piperazinyl

28

3-thienyl

meta

1

CH 2 CO-1-(4-methyl)-piperazinyl

29

3-thienyl

meta

1

CH 2 CO—N-piperazinyl

30

3-thienyl

meta

1

CH 2 CO-1-(4-carboxamide-piperazinyl

31

3-thienyl

meta

1

CH 2 CO-1-(4-propylphenyl)-piperazinyl

32

3-thienyl

meta

1

CH 2 CO-1-(4-propyl)-piperazinyl

33

5-chloro-2-

meta

1

CH 2 CONH 2

thienyl

34

3-thienyl

para

1

CH 2 CO—N-pyrrolidinyl

35

3-thienyl

para

1

CH 2 CONH 2

36

3-thienyl

para

1

CH 2 CON(CH 3 ) 2

37

3-thienyl

para

1

CH 2 CONHCH(CH 3 ) 2

38

3-thienyl

para

1

CH 2 CONHCH 2 CN

39

3-thienyl

para

1

CH 2 CO-1-(4-acetyl)-piperazinyl

40

3-thienyl

para

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

41

3-thienyl

para

1

CH 2 CO-1-(4-methyl)-piperazinyl

42

3-thienyl

para

1

CH 2 CO-1-(4-cyclohexyl)-piperazinyl

43

3-thienyl

para

1

CH 2 CO-1-(4-ethylcarboxylate)-piperazinyl

44

3-thienyl

para

1

CH 2 CO-1-(4-carboxamide)-piperazinyl

45

3-thienyl

para

1

CH 2 CO—N-piperazinyl

46

3-thienyl

para

1

CH 2 CO-1-(4-ethylcarboxamide)-piperazinyl

47

2-benzothienyl

ortho

1

CH 2 CONH 2

48

2-benzothienyl

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

49

2-benzothienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxylate)-piperazinyl

50

2-bentothienyl

ortho

1

CH 2 CO—N-piperazinyl

51

2-benzothienyl

ortho

1

CH 2 CO-1-(4-carboxamide)-piperazinyl

52

2-benzothienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxamide)-piperazinyl

53

2-benzothienyl

ortho

1

CH 2 CO-1-(4-phenylcarboxamide)-piperazinyl

54

2-benzothienyl

ortho

0

CH 2 CONH 2

55

2-benzothienyl

ortho

1

(CH 2 ) 2 CONH 2

56

2-benzotbienyl

ortho

1

(CH 2 ) 2 CO-1-(4-methyl)-piperazinyl

57

2-benzothienyl

ortho

1

CH 2 COOH

58

2-benzothienyl

ortho

2

CH 2 CONH 2

59

2-(1,1-dioxo)-

ortho

2

CH 2 CONH 2

benzothienyl

60

2-benzothienyl

ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

61

3-benzothienyl

ortho

1

CH 2 CONH 2

62

3-benzothienyl

ortho

0

CH 2 CONH 2

63

3-benzothienyl

ortho

1

(CH 2 ) 2 CO-1-(4-methyl)-piperazinyl

64

3-benzothienyl

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

65

3-benzothienyl

ortho

1

CH 2 CO-1-(4-ethylcarboxylate)-piperazinyl

66

3-benzothienyl

ortho

1

CH 2 CO-1-(4-hydroxyethyl)-piperazinyl

67

2-benzothienyl

meta

1

CH 2 CONH 2

68

2-benzotbienyl

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

69

2-benzothienyl

meta

1

CH 2 CO-1-(4-methyl)-piperazinyl

70

2-benzothienyl

meta

1

CH 2 CONHCH(CH 3 ) 2

72

2-benzothienyl

meta

1

CH 2 CO-1-(4-ethylcarboxylate)-piperazinyl

73

2-benzothienyl

meta

1

CH 2 CON(C 2 H 5 ) 2

74

2-benzothienyl

para

1

CH 2 CONH 2

75

2-benzothienyl

para

1

CH 2 CO-1-(4-acetyl)-piperazinyl

76

2-benzothienyl

meta

1

CH 2 CO-1-(4-hydroxyethyl)-piperazinyl

77

3-benzothienyl

meta

1

CH 2 CONH 2

78

3-benzothienyl

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

79

3-benzothienyl

meta

1

CH 2 CO-1-(4-methyl)-piperazinyl

80

3-benzothienyl

meta

1

CH 2 CO-1-(4-hydroxyethyl)-piperazinyl

81

3-benzothienyl

meta

1

CH 2 CO-1-(4-ethylcarboxylate)-piperazinyl

82

2-benzothienyl

para

1

CH 2 CO-1-(4-methyl)-piperazinyl

83

2-benzothienyl

para

1

CH 2 CO-1-(4-hydroxyethyl)-piperazinyl

84

3-benzothienyl

para

1

CH 2 CONH 2

85

2-indolyl

ortho

1

CH 2 CONH 2

86

3-furyl

ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

87

3-furyl

ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

88

3-furyl

ortho

1

CH 2 CONH 2

TABLE 2

Ex.

Ar

No.

Ar

Position

N

q

R

89

3-pyridyl

ortho

1

1

CH 2 CONH(isopropyl)

90

3-pyridyl

ortho

1

1

CH 2 CONH(CH 2 ) 2 OH

91

3-pyridyl

ortho

1

1

CH 2 CONH 2

92

3-pyridyl

ortho

1

1

CH 2 CONH 2

93

3-pyridyl

meta

0

1

CH 2 CONH 2

94

3-pyridyl

meta

1

1

CH 2 CO-1-(4-acetyl)piperazinyl

95

3-pyridyl

meta

1

1

CH 2 CONH(CH 2 ) 2 OH

96

3-pyridyl

meta

2

1

CH 2 CO—N-piperazinyl

97

3-pyridyl

meta

0

1

CH 2 CONH 2

98

3-pyridyl

para

1

I

CH 2 CONH 2

99

3-pyridyl

para

1

1

CH 2 CO-1-(4-acetyl)piperazinyl

100

3-pyridyl

para

2

1

CH 2 CO—N-piperazinyl

101

3-pyridyl

para

1

1

CH 2 CONH(CH 2 ) 2 OH

102

3-pyridyl

para

0

1

CH 2 CONH 2

103

2-furyl

ortho

0

1

CH 2 CON(CH 3 ) 2

104

2-furyl

ortho

0

1

CH 2 CONHCH 2 CN

105

2-furyl

ortho

0

1

CH 2 CONH(isopropyl)

106

2-furyl

ortho

0

1

CH 2 CONH 2

107

2-furyl

ortho

0

1

CH(OCH 3 )CONH 2

108

2-furyl

ortho

0

1

CH 2 CONH(CH 2 ) 2 OH

109

2-furyl

ortho

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

110

2-furyl

ortho

0

1

CH 2 COOH

111

2-furyl

meta

0

1

CH 2 CO—N-pyrrolidinyl

112

2-furyl

meta

0

1

CH 2 CON(CH 3 ) 2

113

2-furyl

meta

0

1

CH 2 CONH(isopropyl)

114

2-furyl

meta

0

1

CH 2 CONHCH 2 CN

115

2-furyl

meta

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

116

2-furyl

meta

0

1

CH 2 CONH(CH 2 ) 2 OH

117

2-furyl

meta

0

1

CH 2 CO—N-(4-piperidinol)

118

2-furyl

meta

1

1

CH 2 CO—N-piperazinyl

119

2-furyl

meta

0

1

CH 2 CONH 2

120

2-furyl

meta

0

1

CH 2 CO-1-[4-(2-

methoxyphenyl)]-piperazinyl

121

2-furyl

meta

0

1

CH 2 CO-1-[4-(4-fluorophenyl)]-

piperazinyl

122

2-furyl

meta

0

1

CH 2 CO-1-(4-phenyl)piperazinyl

123

2-furyl

meta

0

1

CH 2 CONH 2

124

2-seleninyl

meta

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

125

2-hydroxy-

meta

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

phenyl

126

2-benzofuryl

meta

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

127

2-benzofuryl

meta

0

1

CH 2 CONH(CH 2 ) 2 OH

128

2-furyl

para

0

1

CH 2 CONH 2

129

2-furyl

para

0

1

CH 2 CONH(isopropyl)

130

2-furyl

para

0

1

CH 2 CONHCH 2 CN

131

2-furyl

para

0

1

CH 2 CON(CH 3 ) 2

132

2-furyl

para

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

133

2-furyl

para

0

1

CH 2 CONH(CH 2 ) 2 OH

134

2-furyl

para

1

1

CH 2 CO—N-piperazinyl

135

2-thienyl

ortho

0

1

CH 2 CO—N-pyrrolidinyl

136

2-(5-bromo)-

ortho

0

1

CH 2 CO—N-pyrrolidinyl

thienyl

137

2-thienyl

ortho

0

1

CH 2 CON(CH 3 ) 2

138

2-(5-bromo)-

ortho

0

1

CH 2 CON(CH 3 ) 2

thienyl

139

2-thienyl

ortho

0

1

CH 2 CONH 2

140

2-thienyl

ortho

0

1

CH 2 CONH(CH 2 ) 2 OH

141

2-thienyl

ortho

1

1

CH 2 CO—N-piperazinyl

142

2-thienyl

ortho

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

143

2-thienyl

ortho

0

1

CH 2 CONH(isopropyl)

144

2-thienyl

meta

0

1

CH 2 CO—N-pyrrolidinyl

145

2-thienyl

meta

0

1

CH 2 CON(CH 3 ) 2

146

2-thienyl

meta

0

1

CH 2 CONH 2

147

2-thienyl

meta

0

1

CH 2 CONH(CH 2 ) 2 OH

148

2-thienyl

meta

1

1

CH 2 CO—N-piperazinyl

149

2-thienyl

meta

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

150

2-thienyl

para

0

1

CH 2 CO—N-pyrrolidinyl

151

2-(5-bromo)-

para

0

1

CH 2 CO—N-pyrrolidinyl

thienyl

152

2-thienyl

para

0

1

CH 2 CON(CH 3 ) 2

153

2-(5-bromo)-

para

0

1

CH 2 CON(CH 3 ) 2

thienyl

154

2-thienyl

para

0

1

CH 2 CONH 2

155

2-thienyl

para

0

1

CH 2 CONHCH 2 CN

156

2-thienyl

para

0

1

CH 2 CONH(isopropyl)

157

2-thienyl

para

0

1

CH 2 CO-1-(4-acetyl)piperazinyl

158

2-thienyl

para

0

1

CH 2 CONH(CH 2 ) 2 OH

159

2-thienyl

para

1

1

CH 2 CO—N-piperazinyl

436

2-furyl

ortho

0

2

CH 2 CO-1-(4-acetyl)piperazinyl

TABLE 3

Ex.

Ar

No.

Ar

Position

q

R

160

1,3-Dihydro-isoindol-2-yl

ortho

1

CH 2 CO—N-

pyrrolidinyl

161

1,3-Dihydro-isoindol-2-yl

ortho

1

CH 2 CONMe 2

162

1,3-Dihydro-isoindol-2-yl

meta

1

CH 2 CO—N-

pyrrolidinyl

163

1,3-Dihydro-isoindol-2-yl

meta

1

CH 2 CONMe 2

164

1,3-Dihydro-isoindol-2-yl

meta

1

CH 2 CONHCHMe 2

165

1,3-Dihydro-isoindol-2-yl

meta

1

CH 2 CONHCH 2 CN

TABLE 4

Ex.

Ar

No.

Ar

Position

q

R

166

2-Benzofuryl

Ortho

1

CH 2 CO-1-piperazinyl

167

2-Benzofuryl

Ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

TABLE 5

Ex.

Ar

No.

Ar

Position

q

R

168

2-benzo[1,4]-

Ortho

1

CH 2 CO-1-(4-acetyl)-piperazinyl

dioxine

169

2-benzo[1,4]-

Ortho

1

CH 2 CO-1-(4-methyl)-piperazinyl

dioxine

170

2-benzo[1,4]-

Ortho

1

CH 2 CONHCH(CH 3 ) 2

dioxine

TABLE 6

Ex.

Ar

No.

Ar

Position

q

R

171

Pyrrol-1-yl

meta

1

CH 2 CONH(CH 2 ) 2 OH

172

Pyrrol-1-yl

meta

1

CH 2 CO-1-(4-hydroxyl)-piperidinyl

173

Pyrrol-1-yl

meta

1

CH 2 CO-1-(4-acetyl)-piperazinyl

174

Pyrrol-1-yl

ortho

1

CH 2 CONH(CH 2 ) 2 OH

175

Pyrrol-1-yl

ortho

1

CH 2 CO-1-(4-hydroxy)-piperidinyl

176

Pyrrol-1-yl

ortho

1

CH 2 CONH(CH 2 ) 2 O(CH2) 2 OH

TABLE 7

Ex. No.

Ar

Ar Position

q

R

177

Pyrrol-1-yl

ortho

1

CH 2 CO—N-pyrrolidinyl

178

Pyrrol-1-yl

ortho

1

CH 2 CONMe 2

179

Pyrrol-1-yl

ortho

1

CH 2 CONHCHMe 2

180

Pyrrol-1-yl

ortho

1

CH 2 CO-1-(4-acetyl)-

piperazinyl

181

Pyrrol-1-yl

meta

1

CH 2 CONHCH 2 CN

182

Pyrrol-1-yl

meta

1

CH 2 CONHCHMe 2

183

Pyrrol-1-yl

meta

1

CH 2 CONMe 2

TABLE 8

Ex. No.

Ar

Ar Position

q

R

184

2-Benzofuryl

Ortho

1

CH 2 CON(CH 3 ) 2

185

2-Benzofuryl

Ortho

1

CH 2 CONHCH(CH 3 ) 2

TABLE 9

Ex. No.

Ar

Ar Position

q

R

186

Pyrrol-1-yl

ortho

1

CH 2 CONH 2

187

Pyrrol-1-yl

meta

1

CH 2 CONH 2

188

Pyrrol-1-yl

para

1

CH 2 CONH 2

TABLE 10

Ex. No.

Ar

Ar Position

q

R

189

2-benzo[1,4]dioxine

ortho

0

CH 2 CONH 2

190

2-benzo[1,4]dioxine

ortho

1

CH 2 CONH 2

TABLE 11

Ex. No.

Ar

Ar Position

q

R

191

2-Benzofuryl

Ortho

1

CH 2 CONH 2

TABLE 12

Ex. No.

Ar

Ar Position

q

R

192

1,3-Dihydro-isoindol-2-yl

ortho

1

CH 2 CONH 2

193

1,3-Dihydro-isoindol-2-yl

meta

1

CH 2 CONH 2

TABLE 13

Ex.

Biphenyl

No.

Isomer

q

R

194

ortho

1

CH 2 CON(CH 3 ) 2

195

ortho

1

CH 2 CONH 2

196

ortho

1

CH 2 CONHCH 3

197

ortho

1

CH 2 CON(C 2 H 5 ) 2

198

ortho

1

CH 2 CONH(CH 2 ) 2 OH

199

ortho

1

CH 2 CONHCH 2 -(3-pyridyl)

200

ortho

1

CH 2 CONH(cyclobutyl)

201

ortho

1

CH 2 CONH-(cyclopentyl)

202

ortho

1

CH 2 CO—N-pyrrolidinyl

203

ortho

1

CH 2 CO—N-(2-carboxamide)-pyrrolidinyl

205

ortho

1

CH 2 CO—N-piperazinyl

206

ortho

1

CH 2 CO—N-1-(4-t-butylcarboxylate)-piperazinyl

207

ortho

1

CH 2 CO NHCH 2 CN

208

ortho

1

CH 2 CO NHCH 2 CF 3

210

ortho

1

CH 2 CONHCH(CH 3 ) 2

211

para

1

CH 2 CO NH 2

212

para

1

CH 2 CO—N-pyrrolidinyl

213

para

1

CH 2 CO N(CH 3 ) 2

215

Para

1

CH 2 CO—N-piperidinyl

216

para

1

CH 2 CONH(CH 2 ) 2 -(2-pyridyl)

217

para

1

CH 2 CONHCH 2 -(3-pyridyl)

218

Para

1

CH 2 CONHCH(CH 3 ) 2

219

Meta

1

CH 2 CONH 2

220

Meta

1

CH 2 CON(CH 3 ) 2

221

Meta

1

CH 2 CO—N-pyrrolidinyl

222

Meta

1

CH 2 CONHCH(CH 3 ) 2

TABLE 14

Ex.

Substitution on

No.

q

Biphenyl Moiety

n

R

223

1

4′-COCH 3

1

H

224

1

4′-F

1

H

225

1

4′-CH 3

1

H

226

1

2′-CH 3

1

H

227

1

3′,5′-Difluoro

1

H

228

1

3′,5′-Dimethyl

1

H

229

1

3′-F

1

H

230

1

2′-F

1

H

231

1

2′-OEt

1

H

232

1

3′-F,4′-Ph

1

H

233

1

2′-OMe, 5′-F

1

H

234

1

4′-OMe

1

H

235

1

4′-OPh

1

H

236

1

3′-CN

1

H

237

1

3′CONH 2

1

H

238

1

3′,5′-Dichloro

1

H

239

1

3′-CF 3

1

H

240

1

3′-SCH 3

1

H

241

1

3′-SOMe

1

H

242

1

3′-OCF 3

1

H

243

1

3′-CONMe 2

1

H

244

1

4′-OCF 3

1

H

245

1

4′-CF 3

1

H

246

1

4′-SCH 3

1

H

247

1

4′-SOCH 3

1

H

248

1

2′-Cl

1

H

249

1

3′-Cl

1

H

250

1

4′-Cl

1

H

251

1

2′-OMe

1

H

252

1

3′-OMe

1

H

253

1

3′,4′-Dimethoxy

1

H

254

1

3′,4′-Methylenedioxy

1

H

255

1

3′,4′-Ethylenedioxy

1

H

256

1

3′,4′-Propylenedioxy

1

H

257

1

2′,6′-Dimethoxy

1

H

258

1

2′,5′-Dimethoxy

1

H

259

1

3′-NO 2

1

H

260

1

2′-OH

1

H

261

1

3′-OH

1

H

262

1

4′-OH

1

H

263

1

4′-CN

1

H

264

1

3′-Me

1

H

265

1

2′-OCF 3

1

H

266

1

3′-Me, 4′-F

1

H

267

1

2′-SMe

1

H

268

1

3-Cl, 4′-F

1

H

269

1

2′-OMe, 5′-Cl

1

H

270

1

2′-SOMe

1

H

271

1

4,5-(OMe) 2

1

H

272

1

4′-Br

1

H

273

1

2′-OMe, 4′-Cl

1

H

274

1

2′-Me, 4′-Cl

1

H

275

1

2′-Cl, 4′-Cl

1

H

276

1

2′-CF 3

1

H

277

1

2′-F, 4′-Br

1

H

278

2

4′-Cl

1

H

279

1

4′-CHMe 2

1

H

280

1

4′-CMe 3

1

H

281

2

4′-Me

1

H

282

2

4′-F

1

H

283

1

4′-Cl

1

(CH 2 ) 2 OH

284

1

3′-Br

1

H

285

1

2′-Br

1

H

286

1

4′-Cl

1

NHR is replaced by N-

pyrrolidinyl group

287

1

4′-NMe 2

1

H

288

1

4′-CH═CH 2

1

H

289

1

4′-Cl

1

NHR is replaced by 4-

acetylpiperazinyl group

290

1

4′-SO 2 Me

1

H

291

1

3′,4′-Cl 2

1

H

292

1

4′-Et

1

H

293

1

4′-CH 2 OMe

1

H

294

1

4′-CO—N-(4-

1

H

oxo)piperidinyl

295

1

4′-NHSO 2 Me

1

H

296

1

4′-CONMe 2

1

H

298

1

4′-Cyclohexyl

1

H

299

1

3′,4′-F 2

1

H

300

1

3′,4′,5′-OMe 3

1

H

302

1

4′-Cl

2

H

303

1

3′-NMe 2

1

H

304

1

4′-CH 2 CHMe 2

1

H

305

1

5-F, 4′-Cl

1

H

306

1

3′-F, 4′-Cl

1

H

307

1

5-F, 4′-Me

1

H

308

1

5-F, 4′-F

1

H

309

1

5-F, 4′-NMe 2

1

H

310

1

3′-OMe, 4′-Cl

1

H

311

1

3′,4′-F 2 , 5′-OMe

1

H

312

1

3′-CF 3 , 4′-Cl

1

H

313

1

4′-OCH 2 CHMe 2

1

H

314

1

4′-COOMe

1

H

315

1

4′-CH 2 OH

1

H

316

1

4′-COOtBu

1

H

317

1

3′,4′-Me 2

1

H

318

1

3′-CF 3 , 4′-F

1

H

319

1

3′-F, 4′-Me

1

H

320

1

3′-Cl, 4′-Me

1

H

321

1

3′-Me, 4′-Cl

1

H

322

1

4,5-O—CH 2 —O, 4′-Cl

1

H

323

1

4,5-OMe 2 , 4′-Cl

1

H

324

1

4,5-O—CH 2 —O, 4′-F

1

H

325

1

5-F, 3′,4′-F 2

1

H

326

1

4,5-O—CH 2 —O, 4′-Me

1

H

327

1

4,5-O—CH 2 —O,

1

H

3′,4′-F 2

328

1

4,5-OMe 2 , 4′-F

1

H

329

1

4,5-OMe 2 , 4′-Me

1

H

330

1

4,5-OMe 2 , 3′,4′-F 2

1

H

331

1

3′-Me, 4′-OMe

1

H

332

1

5-Cl, 4′-Cl

1

H

333

1

3′,5′-Me 2 , 4′-Cl

1

H

334

1

5-Cl, 4′-F

1

H

335

1

3′-CF 3 , 4′-Me

1

H

336

1

3′-NO 2 , 4′-Cl

1

H

337

1

4-F, 4′-Cl

1

H

338

1

5-Cl, 3′,4′-F 2

1

H

339

2

5-F, 4′-Cl

1

H

340

1

4′-F

2

H

341

1

4-F, 4′-F

1

H

342

1

4-F, 4′-Me

1

H

343

1

4-F, 3′,4′-F 2

1

H

344

2

3′,4′-F 2

1

H

345

1

5-Cl, 4′-Me

1

H

346

1

4-OMe, 4′-Cl

1

H

347

1

6-Me, 4′-Cl

1

H

348

1

6-Me, 3′,4′-Cl 2

1

H

349

1

4-OMe, 3′,4′-Cl 2

1

H

350

1

4-Cl, 4′-Cl

1

H

351

1

4-F, 3′,4′-Cl 2

1

H

352

1

6-Me, 3′-F, 4′-Cl

1

H

TABLE 14A

Ex. No.

Q

Ar

n

R

353

1

cyclohexen-1-yl

1

H

354

1

cyclopenten-1-yl

1

H

355

1

cyclohepten-1-yl

1

H

356

1

Naphth-2-yl

1

H

357

1

phenoxathiin-4-yl

1

H

358

1

Quinolin-3-yl

1

H

359

1

3,5-dimethyl-isoxazol-4-yl

1

H

TABLE 15

Ex. No.

q

Substitution

360

1

6-Me

361

1

2-Me

362

1

4-OMe

363

1

2′-Cl

364

1

3′-Cl

365

1

4′-Cl

366

1

3′,4′-(OMe) 2

367

1

2′-Me, 4′-Cl

368

1

2′-OMe, 4′-Cl

369

1

2′-CN

370

1

2′-Cl, 4′-Cl

371

1

3′-OMe

372

1

4′-OMe

373

1

2′-OMe

374

1

3′-CN

375

1

4′-CN

376

1

2′-Me

377

1

3′-Me

378

1

4′-Me

379

1

2′-F

380

1

3′-F

381

1

4′-F

382

1

3′,4′-Cl 2

383

1

3′,4′-Me 2

384

1

4′-NMe 2

385

1

3′-NMe 2

386

1

4′-Br

387

1

3′-CONH 2

389

1

3′,4′,5′-OMe 3

390

1

3′-CF 3

391

1

3′-NO 2

392

1

3′,4′-F 2

393

1

3′-Cl, 4′-OMe

394

1

4′-Et

395

1

4′-OCF 3

396

1

4′-OCHMe 2

397

1

3′-F, 4′-Cl

398

1

3′-OMe, 4′-Cl

399

1

3′,4′-F 2 , 5′-OMe

TABLE 15A

Ex. No.

q

Ar

400

1

naphtha-2-yl

401

1

3,5-dimethyl-isoxazol-4-yl

TABLE 16

Ex. No.

Q

Substitution

402

1

3-F

403

1

2′-Cl

404

1

3′-Cl

405

1

4′-OMe

406

1

3′,4′-Methylenedioxy

407

1

2′,6′-(OMe) 2

408

1

4′-Cl

409

1

3′,4′-(OMe) 2

410

1

3′-OMe

411

1

4′-CN

412

1

2′,5′-(OMe) 2

413

1

3′-NO 2

414

1

3′-Me

415

1

2′-OMe

416

1

2′-Me, 4′-Cl

417

1

2′-OMe, 4′-Cl

418

1

2′,4′-Cl 2

419

2

3′,4′-(OMe) 2

420

1

3′,4′-Cl 2

421

1

3-F, 4′-Cl

422

1

3-F, 4′-Me

423

1

4′-Br

424

1

3′-Cl, 4′-OMe

425

1

3′,4′,5′-(OMe) 3

426

1

3′,4′-F 2

427

1

3-F, 4′-F

428

2

3-F, 4′-F

429

1

3-F, 4′-Cl

TABLE 16A

Ex. No.

q

Ar

430

1

(3,5-dimethyl)-isoxazol-4-yl

TABLE 17

Ex. No.

Ar

Ar Position

q

R

431

2-benzothienyl

ortho

1

CH 3

432

3-thienyl

ortho

1

CH 3

433

2-furyl

para

1

CH 3

434

2-thienyl

para

1

CH 3

435

phenyl

ortho

1

CH 3

and pharmaceutically acceptable salt forms thereof.

44. A compound selected from 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide, 2-(2-benzo[b]thiophen-5-yl-phenylmethanesulfinyl)-acetamide, 2-[2-(3-chloro-benzofuran-2-yl)-phenylmethanesulfinyl]-acetamide, or the following Table 18:

TABLE 18

Ex. No.

Ar

n

437

4′-fluoro-3-benzothienyl

0

438

4′-fluoro-2-furyl

0

439

4′-fluoro-3-furyl

0

440

4′-fluoro-3-pyridyl

1

441

4′-fluoro-5-chloro-2-thienyl

0

442

5′-chloro-3-pyridyl

1

443

4′-fluoro-3-thienyl

0

444

4′-fluoro-5-chloro-2-benzothienyl

0

and pharmaceutically acceptable salt forms thereof.

45. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipients.

Assignments (2)
MERGER Recorded Jan 24, 2013
From: CEPHALON FRANCE
To: TEVA SANTE
Reel/Frame 029692/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2005
From: CHATTERLEE, SANKAR; BACON, EDWARD R.; DUNN, DEREK; GOURDEL, MARIE-EDITH; HOSTETLER, GREG; IQBAL, MOHAMED; LESUR, BRIGITTE; LOUVEL, PHILIPPE; RIGUET, ERIC; SCHWETZER, DOMINIQUE; YUE, CHRISTOPHE
To: CEPHALON, INC.; CEPHALON FRANCE
Reel/Frame 016663/0222 →